FLT3突变急性淋巴细胞白血病的临床特征

目的：探讨急性淋巴细胞白血病（acute lymphoblastic leukemia，ALL）患者FLT3（Fms-like tyrosine kinase）基因内部串联重复（internal tandem duplication，ITD）与其ASP835（D835）突变（mutation in the tyrosine kinase domain，FLT3-TKD）的发生情况及临床意义。方法采用聚合酶链反应法（polymerase chain reaction， PCR）扩增产物，采用限制性酶切产物分析法分析初诊患者基因易突变区的突变情况。结果147例ALL患者中，11例（7.5%）存在FLT3突变。FLT3突变患者与无突变患者在年龄、性别、骨髓原始细胞计数和外周血原始细胞计数的比较均无统计学意义（均P＞0.05）。T细胞型ALL（T-ALL）患者中FLT3突变的发生率为17.2%，其他类型ALL患者中FLT3突变的发生率为5.1%，差异具有非常显著的统计学意义（P＜0.001）。结论 ALL患者存在FLT3突变，且T-ALL患者的FLT3突变率高于其他类型患者。

The clinical significance of FLT3 mutation in acute lymphoblastic leukemia

Objective To investigate FLT3 mutation-internal tandem duplication (FLT3-ITD) and mutation in the tyrosine kinase domain (FLT3-TKD) in acute lymphoblastic leukemia (ALL) patients and discuss its clinical signifi-cance. Method The FLT3 internal tandem duplication (ITD) and the D835 activating mutation in the tyrosine kinase domain (TKD) were analyzed by polymerase chain reaction (PCR) from genomic DNA and enzyme restriction of PCR product. Result FLT3 mutations were found in 11 patients among 147 ALL patients. There is no difference in age, gender, bone marrow blast percentage, and peripheral blood blast percentage between ALL patients with and without FLT3 mutation(all P>0.05). The incidence of FLT3 mutation in T-ALL is 17.2%, which is significantly higher than that in other type of ALL (5.1%) (P<0.001). Conclusion FLT3 mutation can be detected in ALL. The inci-dence of FLT3 mutation is higher in T-ALL than in other.